These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 25497672)

  • 21. Treatment of metastatic adrenal cortical carcinoma with etoposide (VP-16) and cisplatin after failure with o,p'DDD. Clinical case reports.
    Zidan J; Shpendler M; Robinson E
    Am J Clin Oncol; 1996 Jun; 19(3):229-31. PubMed ID: 8638530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study.
    Bukowski RM; Wolfe M; Levine HS; Crawford DE; Stephens RL; Gaynor E; Harker WG
    J Clin Oncol; 1993 Jan; 11(1):161-5. PubMed ID: 8418229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene.
    Creemers SG; van Koetsveld PM; van den Dungen ES; Korpershoek E; van Kemenade FJ; Franssen GJ; de Herder WW; Feelders RA; Hofland LJ
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4574-4584. PubMed ID: 27603910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells.
    Sbiera S; Leich E; Liebisch G; Sbiera I; Schirbel A; Wiemer L; Matysik S; Eckhardt C; Gardill F; Gehl A; Kendl S; Weigand I; Bala M; Ronchi CL; Deutschbein T; Schmitz G; Rosenwald A; Allolio B; Fassnacht M; Kroiss M
    Endocrinology; 2015 Nov; 156(11):3895-908. PubMed ID: 26305886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mitotane treatment in patients with metastatic testicular Leydig cell tumor associated with severe androgen excess.
    Chortis V; Johal NJ; Bancos I; Evans M; Skordilis K; Guest P; Cullen MH; Porfiri E; Arlt W
    Eur J Endocrinol; 2018 Mar; 178(3):K21-K27. PubMed ID: 29330226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identifying mitotane-induced mitochondria-associated membranes dysfunctions: metabolomic and lipidomic approaches.
    Hescot S; Amazit L; Lhomme M; Travers S; DuBow A; Battini S; Boulate G; Namer IJ; Lombes A; Kontush A; Imperiale A; Baudin E; Lombes M
    Oncotarget; 2017 Dec; 8(66):109924-109940. PubMed ID: 29299119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane.
    Stigliano A; Cerquetti L; Borro M; Gentile G; Bucci B; Misiti S; Piergrossi P; Brunetti E; Simmaco M; Toscano V
    Endocr Relat Cancer; 2008 Mar; 15(1):1-10. PubMed ID: 18310271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatic microsomal enzyme induction and adrenal crisis due to o,p'DDD therapy for metastatic adrenocortical carcinoma.
    Hague RV; May W; Cullen DR
    Clin Endocrinol (Oxf); 1989 Jul; 31(1):51-7. PubMed ID: 2574647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells.
    Germano A; Saba L; De Francia S; Rapa I; Perotti P; Berruti A; Volante M; Terzolo M
    PLoS One; 2018; 13(5):e0196931. PubMed ID: 29734384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Late recurrence of operated adrenocortical carcinoma: atrial natriuretic factor before and after treatment with mitotane.
    Donckier JE; Michel LA; Berbinschi A; De Coster PM; De Plaen JF; Ketelslegers JM; Buysschaert M
    Surgery; 1989 May; 105(5):690-2. PubMed ID: 2523092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells.
    Poli G; Guasti D; Rapizzi E; Fucci R; Canu L; Bandini A; Cini N; Bani D; Mannelli M; Luconi M
    Endocr Relat Cancer; 2013 Aug; 20(4):537-50. PubMed ID: 23722227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.
    Kroiss M; Plonné D; Kendl S; Schirmer D; Ronchi CL; Schirbel A; Zink M; Lapa C; Klinker H; Fassnacht M; Heinz W; Sbiera S
    Eur J Endocrinol; 2016 Mar; 174(3):343-53. PubMed ID: 26671975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.
    Sagawa M; Ohguchi H; Harada T; Samur MK; Tai YT; Munshi NC; Kizaki M; Hideshima T; Anderson KC
    Clin Cancer Res; 2017 Sep; 23(17):5225-5237. PubMed ID: 28442502
    [No Abstract]   [Full Text] [Related]  

  • 34. Effects of mitotane on gene expression in the adrenocortical cell line NCI-H295R: a microarray study.
    Zsippai A; Szabó DR; Tömböl Z; Szabó PM; Eder K; Pállinger E; Gaillard RC; Patócs A; Tóth S; Falus A; Rácz K; Igaz P
    Pharmacogenomics; 2012 Sep; 13(12):1351-61. PubMed ID: 22966885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Adrenocortical tumor, hormonally active, treated with o,p'DDD and hormonally inactive treated surgically].
    Tołłoczko T; Mokrzanowski A
    Pol Tyg Lek; 1980 Jun; 35(23):875-6. PubMed ID: 7413509
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma.
    Kerkhofs TM; Baudin E; Terzolo M; Allolio B; Chadarevian R; Mueller HH; Skogseid B; Leboulleux S; Mantero F; Haak HR; Fassnacht M
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4759-67. PubMed ID: 24057287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells.
    Villa R; Orlandi L; Berruti A; Dogliotti L; Zaffaroni N
    Int J Oncol; 1999 Jan; 14(1):133-8. PubMed ID: 9863019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas.
    Bates SE; Shieh CY; Mickley LA; Dichek HL; Gazdar A; Loriaux DL; Fojo AT
    J Clin Endocrinol Metab; 1991 Jul; 73(1):18-29. PubMed ID: 1675220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of microemulsion of mitotane for improvement of oral bioavailability.
    Attivi D; Ajana I; Astier A; Demoré B; Gibaud S
    Drug Dev Ind Pharm; 2010 Apr; 36(4):421-7. PubMed ID: 19778161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma.
    Hescot S; Seck A; Guerin M; Cockenpot F; Huby T; Broutin S; Young J; Paci A; Baudin E; Lombès M
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2890-8. PubMed ID: 26120791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.